{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 53 of 128', 'Start and stop date of administration (it will also be recorded if the medication is', 'ongoing).', 'Dosage information, including dose, unit, and frequency.', 'Route of administration.', 'For topical treatment, the body location must be recorded; it must also be recorded', 'if the treatment is within 5 cm (approximately 2 inches) of the treatment area.', \"Similarly, any concurrent procedure must also be recorded in the subject's medical record and\", 'the eCRF. The following details will be recorded:', 'Procedure.', 'Body location.', 'Diagnosis.', 'Start and stop date (it will also be recorded if the procedure is ongoing).', 'For topical treatments, it must also be recorded if the procedure is inside the treatment', 'area.', 'Investigators may prescribe concomitant medications or treatments to provide adequate', 'supportive care as deemed necessary, except for medications listed in Section 9.7. Use of', 'emollients is described in Section 9.4.', 'As a rule, the subjects should not change their usual skin care routine if possible. The subjects', 'will be asked to wear vinyl gloves when applying any other skin treatments/products to other', 'areas of the body for other skin conditions during the trial. Normal bathing and washing is', 'allowed with the exceptions mentioned in the instructions for use. Use of cosmetic body care', 'products (e.g., body lotion, shampoo, bath oil), which are routinely used by the subjects, is', 'allowed as per instructions for use, but the products should not be changed during the trial.', 'Excessive sunlight and sunlamps should be avoided. Sunscreen products on the body and', 'protective gloves on the hands are recommended when exposure cannot be avoided.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 54 of 128', '9.7 Prohibited medication and procedures', 'The medications listed in Panel 5 are prohibited during the trial. In case any prohibited', 'treatments are used during the trial, they must be recorded as concomitant medication.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 55 of 128', 'Panel 5: Prohibited medication', 'Medication', 'Prohibited from', 'Prohibited to', 'Systemic treatment with immunosuppressive drugs (e.g.,', '4 weeks prior to', 'End of trial.', 'methotrexate, cyclosporine, azathioprine),', 'baseline.', 'immunomodulating drugs (e.g., janus kinase inhibitors),', 'retinoids (e.g., alitretinoin), or corticosteroids (inhaled or', 'intranasal steroids corresponding to up to 1 mg prednisone', 'for asthma or rhinitis may be used).', 'Phototherapy e.g., PUVA or UVB therapy.', '4 weeks prior to', 'End of trial.', 'baseline.', 'Live attenuated vaccines.', '4 weeks prior to', 'End of trial.', 'baseline.', 'Cutaneously applied treatment with immunomodulators', '2 weeks prior to', 'End of trial.', '(e.g., PDE-4 inhibitors, pimecrolimus, tacrolimus) or topical', 'baseline.', 'corticosteroids on the hands.', 'Cutaneously applied antibiotics on the hands.', '2 weeks prior to', 'End of trial.', 'baseline.', 'Change in systemic antihistamine therapy.', '2 weeks prior to', 'End of trial.', 'baseline.', 'Other cutaneously applied therapy on the hands (except for', '1 week prior to', 'End of trial.', \"the use of subject's own emollient).\", 'baseline.', 'Cutaneously applied treatments in regions other than the', '1 week prior to', 'End of trial.', 'hands, which could interfere with clinical trial evaluations', 'baseline.', 'or pose a safety concern.', 'Treatment with any marketed biological therapy or', 'investigational biologic agents (including immunoglobulin,', 'anti-IgE, and dupilumab):', 'Any cell-depleting agents including but not limited', '6 months prior to', 'End of trial.', 'to rituximab.', 'baseline or until', 'lymphocyte count', 'returns to normal,', 'whichever is longer.', 'Other biologics.', '3 months or 5 half-', 'End of trial.', 'lives, whichever is', 'longer, prior to', 'baseline.', 'Any non-marketed drug substance (i.e., an agent which has', '4 weeks prior to', 'End of trial.', 'not yet been made available for clinical use following', 'baseline or 5 half-lives', 'registration).', 'whichever is the', 'longest.']\n\n###\n\n", "completion": "END"}